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E X ECU TI V E S U M M A RY

These subclassifications are not mutually exclusive. Early-
onset pre-e clampsia is associated with a much higher risk of short-

Pre-eclampsia is a multisystem disorder that typically affects 2%–

and long-term maternal and perinatal morbidity and mortality.

5% of pregnant women and is one of the leading causes of maternal

High-q uality evidence has demonstrated that early-o nset and

and perinatal morbidity and mortality, especially when the condition

preterm pre-e clampsia can be effectively predicted by a Bayes-

is of early onset. Globally, 76 000 women and 500 000 babies die

based method-d erived model that incorporates maternal factors

each year from this disorder. Furthermore, women in low-resource

and a series of biological parameters measured at 11–13+6 weeks

countries are at a higher risk of developing hypertensive disorders of

of gestation. When these high-risk women (with estimated risk

pregnancy and pre-eclampsia compared with those in high-resource

≥1:100) are treated with 150 mg aspirin per night, from 11–

countries. This is because socioeconomic, educational, and environ-

14+6 weeks of gestation at a dose of approximately 150 mg to

mental disadvantages have historically beset vulnerable communi-

be taken every night until 36 +0 weeks of gestation, the rates of

ties, leading to nutritional disparities, poor-quality diet, obesity, and

early-o nset and preterm pre-e clampsia can be reduced by 80%

diabetes (before and during pregnancy), thus increasing the rates of

and 60%, respectively. FIGO (the International Federation of

pregnancy complications, in particular pre-eclampsia.

Gynecology and Obstetrics) endorsed this first-t rimester “screen

Pre-
eclampsia has been traditionally defined as the onset of
hypertension accompanied by significant proteinuria after 20 weeks
of gestation. Recently, the definition of pre-
eclampsia has been

and prevent” strategy for pre-e clampsia and its pragmatic guidance was published in 2019.1
Current wider-scale antenatal care is based on healthcare models

broadened. Now the internationally agreed definition of pre-

developed in the early 20th century. In 1929 the UK Ministry of Health

eclampsia is that proposed by the International Society for the Study

issued a Memorandum on Antenatal Clinics, recommending that

of Hypertension in Pregnancy (ISSHP).

women should first be seen at the 16th week of pregnancy and then

According to ISSHP, pre-
eclampsia is defined as systolic

at 24 and 28 weeks, fortnightly until 36 weeks, and then weekly until

blood pressure at ≥140 mmHg and/or diastolic blood pressure at

delivery. No explicit rationale was offered for the timing or clinical con-

≥90 mmHg on at least two occasions measured 4 hours apart in

tent of visits, yet these guidelines established the pattern of antenatal

previously normotensive women and is accompanied by ≥1 of the

care that has been followed throughout the world to the present day.

following new-onset conditions at or after 20 weeks of gestation:

A common assumption has prevailed that antenatal care should
be concentrated around the third trimester of pregnancy, where

• Proteinuria: 24-hour urine protein ≥300 mg/day; spot urine pro-

most complications clinically materialize and adverse outcomes can

tein/creatinine ratio ≥30 mg/mmoL or ≥0.3 mg/mg, or urine dip-

be diagnosed. The current method of monitoring for pre-eclampsia

stick testing ≥2+

is based on this 90-year-old care pathway that requires that at every

• Other maternal organ dysfunction:

clinical visit, women are assessed for hypertension and proteinuria.
However, even in the case of early-onset disease, this approach

-	 Acute kidney injury (creatinine ≥90 µmol/L; >1.1 mg/dL);

detects hypertension and pre-eclampsia only at a late stage of pre-

-	 Liver involvement (such as elevated liver transaminases

sentation, which does not necessarily allow optimization of care

>40 IU/L) with or without right upper quadrant or epigastric

for both the mother and the fetus, namely stabilization of blood

pain;

pressure, prophylactic corticosteroid for fetal lung maturation, and

-	 Neurological complications (including eclampsia, altered mental status, blindness, stroke, or more commonly hyperreflexia
when accompanied by clonus, severe headaches, and persistent visual scotomata);
-	 Hematological

complications

transferal to a tertiary referral unit prior to the need for immediate
delivery, which is the only definitive treatment for this disorder.
In the past decade, major efforts have been made to develop
tools for risk stratification and prediction of pre-eclampsia in high-

(thrombocytopenia–platelet

risk women, as well as short-term prediction in women presenting

count <150 000/µL, disseminated intravascular coagulation,

with signs and symptoms of pre-eclampsia and those with confirmed

hemolysis);

pre-eclampsia. FIGO brought together international experts to dis-

-		 Uteroplacental dysfunction (such as fetal growth restriction,

cuss and evaluate current knowledge on the topic and develop a

abnormal umbilical artery Doppler wave form or stillbirth).

document to frame the issues and suggest key actions to address
the health burden posed by pre-eclampsia.

Pre-eclampsia can be subclassified into:

FIGO’s objective, as outlined in this document, is: (1) to raise
awareness of the links between pre-
eclampsia and poor mater-

1. Early-
onset pre-
eclampsia (with delivery at <34+0 weeks of
gestation).

nal and perinatal outcomes as well as of the future health risks to
mother and offspring, and demand a clearly defined agenda to tackle

+0

2. Preterm pre-eclampsia (with delivery at <37 weeks of gestation).

this issue globally; and (2) to create a consensus document, which

3. Late-onset pre-eclampsia (with delivery at ≥34+0 weeks of

provides guidance on prediction, risk stratification, monitoring, and

gestation).
4. Term pre-eclampsia (with delivery at ≥37+0 weeks of gestation).

management of pre-eclampsia in the second and third trimester of
pregnancy, and to disseminate and encourage its use.
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Based on high-quality evidence, the document outlines current

should be treated with antihypertensive therapy with the target to

global standards for the risk stratification, monitoring, and manage-

achieve systolic blood pressure and diastolic blood pressure equal to or

ment of pre-eclampsia in the second and third trimester of pregnancy.

below 135 and 85 mmHg, respectively. Oral labetalol, nifedipine, and

It provides the most pragmatic advice for different resource

methyldopa should be considered as first-line antihypertensive agents

settings—keeping in mind the feasibility, acceptability, and ease of

for nonsevere hypertension. Severe hypertension (systolic blood pres-

implementation of the advice—to significantly lessen the health and

sure ≥160 mmHg or diastolic blood pressure ≥110 mmHg) should be

economic burden caused by pre-eclampsia. Suggestions are provided

treated urgently with antihypertensive therapy in a monitored setting.

for a variety of different regional and resource settings based on their

Severely elevated diastolic blood pressure should be lowered to a tar-

financial, human, and infrastructure resources, as well as for research

get of 85 mmHg, but gradually over hours to days. Oral nifedipine, oral

priorities to bridge the current knowledge and evidence gap.

labetalol, intravenous labetalol, and intravenous hydralazine are con-

To address pre-eclampsia, FIGO recommends the following:

sidered as first-line antihypertensive agents for severe hypertension.

Public health focus: there should be greater international

Magnesium sulfate is recommended for the prevention of eclampsia as

attention focused on pre-

eclampsia and to the links between

well as a neuroprotective agent for the prevention of perinatal morbid-

maternal health and noncommunicable diseases on the Sustainable

ity in preterm pre-eclampsia requiring delivery at <32 weeks.

Developmental Goals agenda. Public health measures to increase

Delivery plans for women with confirmed pre-eclampsia: deliv-

awareness, access, affordability, and acceptance of preconception

ery for pre-eclampsia at any gestational age is recommended when

counselling and antenatal and postnatal services for women of

there is one or more of the following conditions: abnormal neuro-

reproductive age should be prioritized. Greater efforts are required

logical features such as severe intractable headache, repeated visual

to raise awareness of the benefits of early antenatal visits targeted at

scotomata, eclampsia, or stroke; repeated episodes of severe hyper-

women of reproductive age, particularly in low-resource countries.

tension despite maintenance treatment with three classes of anti-

Risk stratification and monitoring in asymptomatic women:

hypertensive agents; pulmonary edema or oxygen saturation <90%;

appropriate antenatal maternal and fetal surveillance should be put

progressive thrombocytopenia (particularly <50 × 109/L or need for

in place for high-risk women for pre-eclampsia. Where resources

transfusion); abnormal and rising serum creatinine; abruption with

permit, the following could be included: guidance on recognition of

evidence of maternal or fetal compromise; nonreassuring fetal status

symptoms and when to seek care; home blood pressure monitoring;

(including intrauterine fetal death). Mode of delivery is determined by

regular formal clinical assessment (blood pressure measurement,

several factors that include gestational age, fetal condition, and other

dipstick proteinuria assessment and, where available, testing for

concurrent obstetrics factors such as previous cesarean section.

hemoglobin, platelet count, serum creatinine, and liver transami-

Postpartum care: blood pressure should continue to be moni-

nases); fetal ultrasonographic assessment of growth and umbilical

tored after delivery until 6 days after birth, as it is likely to be high-

artery Doppler; assessment of uterine artery Doppler.

est 3–6 days after birth. Antihypertensive therapy that has been

Management of women with confirmed pre-eclampsia: women

administered before birth should be continued after birth for as

with pre-eclampsia should be assessed in hospital when first diagnosed.

long as required to maintain blood pressure control. Consideration

Thereafter, some women may be managed as outpatients once it is

should be given to administering antihypertensive therapy for any

established that their condition is stable and they can be relied upon to

hypertension diagnosed up to 6 days after delivery. Hypertensive

monitor blood pressure at home and seek medical advice when there is

pregnancy disorders should be acknowledged as predictors of long-

rising/raised blood pressure. Appropriate antenatal maternal and fetal

term maternal cardiovascular morbidity. The following measures

surveillance should be put in place. Where resources permit, the follow-

should be implemented at 6–12 weeks after birth, and periodically

ing could be included: maternal assessment by components of PIERS

thereafter, preferably yearly, following a pregnancy complicated

models (Pre-eclampsia Integrated Estimate of Risk Scores), maternal

by hypertensive disorders: history and physical examination, blood

laboratory testing, fetal ultrasonographic assessment of growth, umbil-

pressure measurements, and consideration of screening for other

ical artery Doppler, and fetal cardiotocography. At ≥32 weeks, if there

cardiovascular risk factors and for diabetes according to additional

is no access (or access is not yet possible) to fetal cardiotocography and

risk factors.

ultrasound, the following should be used to assess fetal risk in hyper-

Automated blood pressure devices: Only automated blood pres-

tensive pregnancy: maternal age, symptoms, and dipstick proteinuria.

sure devices that have been shown to be accurate in pregnancy and

For nonsevere hypertension management, elevated blood pressure

pre-eclampsia should be used.
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TA RG E T AU D I E N C E

practitioners/family physicians, midwives, nurses, advance practice
clinicians, nutritionists, pharmacists, community health workers,

This document is directed at multiple stakeholders with the inten-

laboratory technicians, etc).

tion of bringing attention to pre-eclampsia, which is a common and

Healthcare delivery organizations and providers: governments,

potentially life-threatening complication of pregnancy with grave

federal and state legislators, healthcare management organizations,

consequences for both mothers and offspring. This document pro-

health insurance organizations, international development agencies,

poses to create a global framework for action for risk stratification,

and nongovernmental organizations.

monitoring, and management of pre-eclampsia.

Professional organizations: international, regional, and national

The intended target audience includes:

professional organizations of obstetricians and gynecologists,

Healthcare providers: all those qualified to care for pregnant

internists, family practitioners, pediatricians, neonatologists, and

women and their newborns but in particular those responsible

worldwide national organizations dedicated to the care of pregnant

for managing high-risk women (obstetricians, maternal-fetal med-

women with pre-eclampsia.

icine specialists, internists, pediatricians, neonatologists, general

|
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language and graphical descriptions for the strength and quality of
the recommendations and the evidence on which they are based.
Strong recommendations are numbered as 1 and conditional (weak)
recommendations are numbered 2 (Table 1). For the quality of

In assessing the quality of evidence and grading of strength of recommendations, this document follows the terminology proposed by
the Grading of Recommendations, Assessment, Development and
Evaluation (GRADE) working group. 2 This system uses consistent

evidence, cross-filled circles are used: ⊕OOO denotes very low-

quality evidence; ⊕⊕OO low quality; ⊕⊕⊕O moderate quality;

and ⊕⊕⊕⊕ high quality evidence (Table 2).

TA B L E 1 Interpretation of strong and conditional (weak) recommendations according to GRADEa,b
2 = Conditional (weak) recommendation
phrased as “we suggest”

Implications

1 = Strong recommendation phrased as “we recommend”

For patients

Nearly all patients in this situation would accept the recommended
course of action. Formal decision aids are not needed to help patients
make decisions consistent with their values and preferences

Most patients in this situation would accept
the suggested course of action

For clinicians

According to the guidelines, performance of the recommended action
could be used as a quality criterion or performance indicator

Decision aids may help patients make a
management decision consistent with their
values and preferences

For policy makers

The recommendation can be adapted as policy in most situations

Stakeholders need to discuss the suggestion

a

Adapted with permission of the American Thoracic Society. © 2021 American Thoracic Society. All rights reserved. Schunemann HJ, Jaeschke R,
Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations.
Am J Respir Crit Care Med 2006;174:605–614. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American
Thoracic Society. Readers are encouraged to read the entire article for the correct context at: https://www.atsjournals.org/doi/full/10.1164/
rccm.200602-197ST. The authors, editors, and The American Thoracic Society are not responsible for errors or omissions in adaptations.

b

Both caregivers and care recipients need to be involved in the decision-making process before adopting recommendations.

TA B L E 2 Interpretation of quality of evidence levels according to GRADEa

a

Level of evidence

Definition

High
⊕⊕⊕⊕

We are very confident that the true effect corresponds to that of the estimated effect

Low
⊕⊕⃝⃝

Our confidence in the estimated effect is limited. The true effect could be substantially different
from the estimated effect

Moderate
⊕⊕⊕⃝

We are moderately confident in the estimated effect. The true effect is generally close to the
estimated effect, but it may be slightly different

Very low
⊕⃝⃝⃝

We have very little confidence in the estimated effect. The true effect is likely to be substantially
different from the estimated effect

Adapted with permission from Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality
of evidence. J Clin Epidemiol. 2011;64(4):401–4 06. © 2011 Elsevier.
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PR E- E C L A M P S I A : BAC KG RO U N D

4.1 | Introduction

Box 1 Diagnosis of hypertensive disorders in
pregnancy according to the Society for the Study of
Hypertension in Pregnancy6

Pre-eclampsia is a multisystem disorder of pregnancy previously

Gestational hypertension:

defined by the onset of hypertension accompanied by significant

• Persistent de novo hypertension (systolic blood pressure

proteinuria after 20 weeks of gestation. Recently the definition

≥140 mmHg and/or diastolic blood pressure ≥90 mmHg)

of pre-eclampsia has been broadened.3–6 Pre-eclampsia typically

after 20 weeks of gestation in the absence of features of

affects 2%–5% of pregnant women and is one of the leading causes

pre-eclampsia.

of maternal and perinatal morbidity and mortality, especially when

Pre-eclampsia de novo:

the condition is of early onset.7,8 Globally, 76 000 women and

• Gestational hypertension accompanied by ≥1 of the fol-

500 000 babies die each year from this disorder.9 Furthermore,

lowing new-onset conditions at or after 20 weeks of

women in low-resource countries are at a higher risk of developing

gestation:

hypertensive disorders of pregnancy and pre-eclampsia compared

-	 Proteinuria: 24-hour urine protein ≥300 mg/day;

with those in high-resource countries. This is because socioeco-

spot urine protein/creatinine ratio ≥30 mg/mmoL or

nomic, educational, and environmental disadvantages have histori-

≥0.30 mg/mg, or urine dipstick testing ≥2+

cally beset vulnerable communities leading to nutritional disparities,

-	 Other maternal organ dysfunction:

poor-quality diet, obesity, and diabetes (before and during preg-

▪ Acute kidney injury (creatinine ≥90 µmol/L; >1.1 mg/

nancy), thus increasing the rates of pregnancy complications. FIGO

dL);

(the International Federation of Gynecology and Obstetrics) has pro-

▪ Liver involvement (such as elevated alanine ami-

vided pragmatic guidance on addressing the management of hyper-

notransferase (ALT) or aspartate transaminase (AST)

10,11

>40 IU/L with or without right upper quadrant or epi-

glycemia, nutrition, and obesity care during and after pregnancy.

gastric pain);
▪ Neurological

4.2 | Definition of pre-eclampsia

complications

(including

eclampsia,

altered mental status, blindness, stroke, or more commonly hyperreflexia when accompanied by clonus,

Pre-eclampsia is traditionally defined as development of hypertension and new proteinuria in a previously normotensive woman. The
difficulty in interpreting epidemiological studies of pre-eclampsia is
due to the wide variation in the definitions of the disease. There are

severe headaches, and persistent visual scotomata);
▪ Hematological

complications

(thrombocytopenia–

platelet count <150 000/µL, disseminated intravascular coagulation, hemolysis);

several definitions for the diagnosis of pre-eclampsia, which have

▪ Uteroplacental dysfunction (such as fetal growth

been reported in published literature and proposed by various pro-

restriction, abnormal umbilical artery Doppler wave

fessional bodies. Consequently, this has resulted in a number of dif-

form or stillbirth).

ferent guidelines produced by professional bodies worldwide for

Superimposed pre-eclampsia on chronic hypertension:

the diagnosis and management of pre-eclampsia.3,12–14 An interna-

• Women with chronic essential hypertension develop

tionally agreed definition of pre-eclampsia is, however, that of the

any of the above maternal organ dysfunctions consist-

International Society for the Study of Hypertension in Pregnancy

ent with pre-eclampsia.

6

(ISSHP) (Box 1), which is endorsed by FIGO.

• Increase in blood pressure per se is not sufficient to

As described in the FIGO initiative on pre-eclampsia, published in
2019,1 according to the associated risks of maternal and perinatal morbidity and mortality, pre-eclampsia can be further subclassified into:

diagnose superimposed pre-eclampsia.
• In the absence of pre-existing proteinuria, new-onset
proteinuria in the setting of a rise in blood pressure is
sufficient to diagnose superimposed pre-eclampsia.

1. Early-
onset pre-
eclampsia (with delivery at <34+0 weeks of
gestation).

In women with proteinuric renal disease, an increase in
proteinuria during pregnancy is not sufficient per se to

2. Preterm pre-eclampsia (with delivery at <37+0 weeks of gestation).
+0

3. Late-onset pre-eclampsia (with delivery at ≥34

weeks of

gestation).

diagnose superimposed pre-eclampsia.
Refer to Section 7.4 “Antihypertensive therapy” for the
definition of severe hypertension.

4. Term pre-eclampsia (with delivery at ≥37+0 weeks of gestation).
These subclassifications are not mutually exclusive. High-quality
evidence has demonstrated that early-onset and preterm pre-eclampsia

parameters measured at 11–13+6 weeks of gestation.15 When these

can be effectively predicted by a Bayes-
based method-
derived

high-risk women (with estimated risk ≥1:100) are treated with 150 mg

model that incorporates maternal factors and a series of biological

aspirin per night, from 11–14+6 weeks of gestation until 36+0 weeks

|
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of gestation, the rates of early-onset and preterm pre-eclampsia can
16

be reduced by 80% and 60%, respectively.

11

pre-e clampsia exhibit high circulating serum levels of fms-like

FIGO has endorsed this

tyrosine kinase 1 (sFlt-1) and low levels of placental growth fac-

first-trimester “screen and prevent” strategy for pre-eclampsia and its

tor (PLGF). 20 Experimentally, iatrogenic overexpression of sFlt-1

1

pragmatic guidance was published in 2019. In the present guidance,

in pregnant rats leads to hypertension, proteinuria, and glomeru-

we focus on the risk stratification, monitoring, and management of

lar endotheliosis—a histological hallmark of pre-e clampsia. In a

pre-eclampsia in the second and third trimester of pregnancy.

baboon model for pre-e clampsia (uterine ligation), restoring the
angiogenic balance by application of recombinant human PLGF
(rhPLGF) ameliorated pre-e clampsia symptoms, such as hyper-

4.3 | Pathophysiology of pre-eclampsia

tension and proteinuria. 21 Application of short interfering RNAs
(siRNAs) leads to reduction of blood pressure and proteinuria via

Pre-e clampsia is a heterogeneous, multifactorial syndrome and

silencing of sFlt-1 expression in experimental models (primates

its etiology is far from understood. Details on the different eti-

and mice). In humans, extracorporeal removal of excessively

ological hypotheses are beyond the scope of this best practice

elevated sFlt-1 in women with early-o nset pre-e clampsia led to a

17–19

However,

prolongation of the disease. 22,23 These lines of evidence highlight

important understanding of the pathophysiology of the dis-

the concept of a disturbed angiogenic balance as being central to

ease has been gained by the discovery of the disturbed angio-

the pathophysiology of the disease. This has led to the develop-

genic and antiangiogenic balance in women destined to develop

ment of sFlt-1 and PLGF as markers for diagnosis, prognostica-

pre-
e clampsia and associated adverse events. Women with

tion, and prediction of the disease, as discussed below.

advice. Specific reviews can be found elsewhere.

12
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pre-e clampsia is based on this 90-year-o ld care pathway that requires that at every clinical visit, women are assessed for hypertension and proteinuria. However, even in the case of early-o nset

Current wider-scale antenatal care is based on healthcare models de-

disease, this approach detects hypertension and pre-e clampsia

veloped in the early 20th century. In 1929 the UK Ministry of Health

only at a late stage of presentation, which does not allow op-

issued a Memorandum on Antenatal Clinics, recommending that

timization of care for both the mother and the fetus, namely

women should first be seen at the 16th week of pregnancy and then at

stabilization of blood pressure, prophylactic corticosteroid for

24 and 28 weeks, fortnightly until 36 weeks, and then weekly until de-

fetal lung maturation, and transfer to a tertiary referral unit prior

livery.24 No explicit rationale was offered for the timing or clinical con-

to the need for immediate delivery, which is the only definitive

tent of visits, yet these guidelines established the pattern of antenatal

treatment for this disorder.

care that has been followed throughout the world to the present day.
A common assumption has prevailed that antenatal care

In the past decade, major efforts have been made to develop
tools for risk stratification and prediction of pre-eclampsia in high-

should be concentrated around the third trimester of pregnancy,

risk women, as well as short-term prediction in women presenting

where most complications clinically materialize and adverse out-

with signs and symptoms of pre-eclampsia. An overview of the ex-

comes can be diagnosed. The current method of monitoring for

isting literature is summarized in the following section.

|
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6 | R I S K S TR ATI FI C ATI O N O F PR E-
EC L A M P S I A I N TH E S ECO N D A N D TH I R D
TR I M E S TE R S O F PR EG N A N C Y
6.1 | Short-term prediction in women presenting
with signs and symptoms of pre-eclampsia

13

disease. While angiogenic markers may be of value in pre-eclampsia
given the number of women with both hypertension and dipstick
proteinuria at baseline, this remains to be established. In addition,
further work is needed to establish the value of repeated PLGF measurements in women presenting with suspected or confirmed pre-
eclampsia, particularly after 35 weeks.
It is important to mention that currently there are four PLGF-

6.1.1 | Placental growth factor

based tests commercially available. Furthermore, that PLGF has
different isoforms. The specific rule in/out criteria are dependent

In addition to their use as a first-trimester screening tool, PLGF-based

on the exact assay (which have different detection characteristics

tests have been shown to have high diagnostic accuracy in women

depending on which isoform of PLGF is detected), and whether a

with suspected pre-
eclampsia. A recent prospective multicenter

ratio of sFlt-1 to PLGF is used. In addition, the prevalence of pre-

study demonstrated that low circulating maternal PLGF concentra-

eclampsia, or the endpoint used, is variable in the different clinical

tions had high sensitivity (96%; 95% CI, 89–99) and negative pre-

studies using different assays, making direct comparison between

dictive value (98%; 95% CI, 93.0–99.5) in diagnosing pre-eclampsia

studies difficult as the predictive values are highly dependent on

that required delivery within 14 days in women who presented with

prevalence in the given setting.

suspected pre-eclampsia. 25

The COMPARE study27 evaluated three of these assays in the

This UK PELICAN study25 showed that the Triage PLGF test at a

same population of women, using the manufacturer's recommended

cutoff of 100 pg/mL (with ≥100 pg/mL considered a normal result)

cutoffs: Triage PLGF test (Quidel Corporation, San Diego, CA, USA),

had a negative predictive value of 98% when used to rule out pre-

the DELFIA-
Xpress PLGF 1-
2-
3-
test (PerkinElmer Inc., Waltham,

eclampsia that needed delivery within the next 14 days. Ruling in

MA, USA), and the Elecsys immunoassay sFlt-1/PLGF ratio (Roche

women with an abnormal result of less than 12 pg/mL (the lower

Diagnostics, Mannheim, Germany) (Table 3). Similar performance

limit of detection) yielded high specificity (>90%) for the same end-

was demonstrated in the prediction of need for delivery within

point. These tests were valid in women presenting with suspected

14 days in women with suspected pre-eclampsia.

pre-
eclampsia, which includes women with hypertension, pro-

The ultimate choice of which assay to use will depend on cost,

teinuria, fetal growth restriction, or symptoms suggestive of pre-

availability, and clinical utility such as ease of use. All current tests

eclampsia such as headaches or epigastric pain. The test works well

appear to be valuable. The Triage PLGF test and the Elecsys immu-

between 20 and 34+6 weeks of gestation. The test has some value

noassay sFlt-1/PLGF ratio have been recommended by the National

after 35 weeks (up to 37 weeks) but is not as good. 25

Institute for Health and Care Excellence (NICE) as a rule-out test for

The authors went on to implement these thresholds in a prag-

pre-eclampsia at less than 35 weeks.31 The National Health Service

matic stepped-wedge trial to see if knowledge of the test influenced

(NHS) England has funded initiatives to roll out these tests nationally

behaviors and outcomes. The PARROT trial demonstrated that at an

for suspected pre-eclampsia at less than 35 weeks.

average of 32 weeks of gestation, the availability of PLGF results
(using the Triage PLGF test) substantially reduced the time to clinical
confirmation of pre-eclampsia (1.9 vs 4.1 days; time ratio 0.36; 95%
CI, 0.15–0.87; P = 0.027) and reduced adverse maternal outcomes

6.1.2 | Soluble fms-like tyrosine kinase 1 to
placental growth factor ratio

(4% vs 5%; adjusted odds ratio 0.32, 95% CI, 0.11–0.96; P = 0.043),
supporting the adoption of PLGF-based testing into routine clinical

The role of the sFlt-1/PLGF ratio to predict adverse outcomes

practice. 26

related to pre-e clampsia was investigated in a prospective study

The high negative predictive value of PLGF-based tests sup-

with 616 women presenting with signs and symptoms of the dis-

ports their use as a “rule out” tool in women with suspected dis-

ease. 32 Women were eligible for enrolment when they presented

ease preterm. We suggest their use alongside clinical assessment to

with either elevated blood pressure or proteinuria and/or symp-

help rule out pre-eclampsia in women suspected of developing the

toms such as headache, visual symptoms, right upper quadrant

TA B L E 3 Rule-in and rule-out thresholds of commercially available assays
Triage PLGF test

Elecsys
sFlt-1/PLGF ratio

DELFIA Xpress PLGF 1-2-3
test

BRAHMS
sFlt-1/PLGF plus ratio

Recommended rule-out
threshold

≥100 pg/mL

≤38

≥150 pg/mL

>55

Suggested rule-in threshold

<12 pg/mL

Relevant study

25

PELICAN
PARROT26

>85

<50 pg/mL

>188

PROGNOSIS28
INSPIRE29

COMPARE27

Cheng et al.30
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pain, or edema. The primary endpoint was the development of ma-

value of 94.3% (95% CI, 91.7–96.3). 33 Evidence from this analy-

ternal and/or fetal adverse events related to pre-e clampsia within

sis shows the importance of repeated measurements in women

2 weeks. Maternal adverse events were defined as a combination

with signs and symptoms of the disease. Women with suspected

of hypertension and abnormal liver function tests, disseminated in-

pre-e clampsia who developed the disorder had a significantly

travascular coagulation, pulmonary edema, or eclampsia. Fetal ad-

larger median increase in the sFlt-1/PLGF ratio at 2 weeks (delta

verse events included indicated delivery, fetal growth restriction,

[Δ] 31.22) and 3 weeks (Δ48.97) after the first blood draw, com-

or fetal or neonatal death. Adverse events occurred in 43.5% of all

pared with those who did not (Δ1.45 and Δ2.39, respectively;

patients (n = 268) and in 33.5% of women presenting at less than

P < 0.001).

34 weeks of gestation (n = 59). Women who had an adverse event

These results were validated in the PROGNOSIS Asia study.34

related to pre-e clampsia had a significantly elevated sFlt-1/PLGF

This multicenter study enrolled 764 women with suspected pre-

ratio compared with those who did not (47.0, interquartile range

eclampsia in 25 centers in Asia. Suspected pre-eclampsia was de-

[IQR] 15.5–112.2 vs 10.8, IQR 4.1–28.6; P < 0.001). In women who

fined as in the PROGNOSIS study; however, only severe persistent

presented at less than 34 weeks of gestation (n = 176), the results

epigastric pain and new onset of visual disturbances were consid-

were more striking (226.6, IQR 50.4–5 47.3 vs 4.5, IQR 2.0–13.5;

ered as potential symptoms related to pre-eclampsia. In this study an

P < 0.001). For women who presented before 34 weeks of ges-

sFlt-1/PLGF ratio cutoff of ≤38 was shown to have a negative predic-

tation, the addition of the sFlt-1/PLGF ratio to hypertension and

tive value of 98.6% (95% CI, 97.2–99.4) for ruling out pre-eclampsia

proteinuria significantly improved the prediction for subsequent

within 1 week and a ratio >38 demonstrated a positive predictive

adverse outcomes (area under the receiver operating character-

value of 30.3% (95% CI, 23.0–38.5) for ruling in pre-eclampsia within

istic curve (AUC) 0.93 for hypertension, proteinuria, and sFlt-1/

4 weeks. The positive predictive value for the occurrence of a com-

PLGF ratio versus 0.84 for hypertension and proteinuria alone;

bined endpoint of pre-
eclampsia/eclampsia/HELLP syndrome or

P < 0.001). Delivery occurred within 2 weeks of presentation in

maternal and/or fetal adverse outcomes within 4 weeks was 65.0%

86.0% of women with an sFlt-1/PLGF ratio greater than 85 com-

(95% CI, 56.6–72.8).34

pared with 15.8% of women with an sFlt-1/PLGF ratio less than 85
(hazard ratio, 15.2; 95% CI, 8.0–28.7). 32

A prospective cohort study of nulliparous women investigated
the added value of the sFlt-1/PLGF ratio in a high-risk and low-risk

In the PROGNOSIS study, 28 a prospective observational study

population. 35 High-risk of pre-eclampsia was defined as either: (1)

conducted in 14 countries, the ability of the sFlt-1/PLGF ratio to

maternal characteristics, using the UK NICE guideline; or (2) ele-

predict the absence of pre-eclampsia within 1 week and to pre-

vated 20 weeks uterine artery Doppler, defined as a mean pulsa-

dict the presence of pre-eclampsia within 4 weeks in women with

tility index in the highest decile. Blood sampling was performed at

signs and symptoms of pre-eclampsia was investigated. This study

approximately 20, 28, and 36 weeks. The primary outcomes were

included 1050 pregnant women aged 18 years or older at 24–

pre-eclampsia and delivery <28 weeks or pre-eclampsia and deliv-

36+6 weeks of gestation with clinical symptoms of the disease such

ery <37 weeks (for 20 weeks sample); pre-eclampsia and delivery

as new onset of hypertension or aggravation of pre-existing hyper-

<37 weeks (28 weeks sample); and pre-eclampsia with severe fea-

tension; new onset of proteinuria or aggravation of existing pro-

tures (36 weeks sample). A total of 4099 women were recruited,

teinuria; the presence of typical symptoms of the disease such as

the incidence of pre-eclampsia was 6.5% (265/4099) in total, 0.1%

headache, right upper quadrant abdominal pain, edema, or weight

before 28 weeks, 0.65% before 36 weeks, and 2.8% developed

gain; as well as an abnormal uterine artery Doppler. The prevalence

severe pre-eclampsia after 36 weeks. The screening performance

of pre-eclampsia in the full dataset was 17.8%. In the development

at 20, 28, and 36 weeks was 0.70 (95% CI, 0.43–0.97), 0.80 (95%

cohort of 500 women, the single cutoff of 38 was found to be

CI, 0.70–0.89), and 0.81 (95% CI, 0.77–0.86), respectively. Women

predictive for the primary endpoint, which was then evaluated in

with an sFlt-1/PLGF ratio >38 (n = 19) at 28 weeks had an inci-

the validation cohort of another 550 women. In women with sus-

dence of pre-eclampsia of 32% leading to preterm delivery. The

pected pre-eclampsia according to the PROGNOSIS criteria, the

positive predictive value was similar in low-and high-risk women

negative predictive value of an sFlt-1/PLGF ratio ≤38 for ruling out

(33% vs 31%, P = 0.91). At 36 weeks, women with an sFlt-1/PLGF

the occurrence of pre-eclampsia within 1 week was 99.3% (95% CI,

ratio >38 (n = 566) had an incidence of severe pre-eclampsia of

97.9–99.9). The positive predictive value of an sFlt-1/PLGF ratio

10%. Among women with no prior risk factors, an sFlt-1/PLGF ratio

>38 for ruling in the occurrence of pre-eclampsia within 4 weeks

≤38 had a high negative predictive value for subsequent develop-

was 36.7% (95% CI, 28.4–45.7). The positive predictive value for

ment of severe disease (>99%). Sovio et al. 35 tested the cutoffs of

the occurrence of a combined endpoint of pre-eclampsia/eclamp-

85 (<34 weeks) and 110 (>34 weeks) in their cohort. Four out of

sia/HELLP syndrome (hemolysis, elevated liver enzymes, and low

seven women with an sFlt-1/PLGF ratio >85 at 28 weeks deliv-

platelet count) or maternal and/or fetal adverse outcomes within

ered preterm with a diagnosis of pre-eclampsia (positive predictive

4 weeks was 65.5% (95% CI, 56.3–74.0).

28

value 57%). At 36 weeks, 70 women had an sFlt-1/PLGF ratio >110

In an exploratory post hoc analysis of the PROGNOSIS data-

and 21 developed severe disease (positive predictive value 30%).

set it was demonstrated that an sFlt-1/PLGF ratio of ≤38 can

The positive predictive value was similar comparing women with

rule out pre-e clampsia within 4 weeks with a negative predictive

and without prior risk factors (36% and 24%, respectively). 35
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6.2 | Risk stratification and monitoring in asymptomatic high-risk women
6.2.1 | Antenatal maternal and fetal surveillance
Strength of
recommendation

Best practice advicea

Quality of evidence

Pregnant women who screen positive as high risk for pre-eclampsia and the related
placental disorders of gestational hypertension, fetal growth restriction, and stillbirth
should be offered increased antenatal maternal and fetal surveillance.

Low
⊕⊕OO

Strong

In high-risk women, antenatal maternal surveillance should include guidance on recognition
of symptoms (e.g. headache, visual disturbances, chest pain, dyspnea, epigastric pain,
right upper quadrant pain, or vaginal bleeding) and when to seek care.

Low
⊕⊕OO

Strong

In high-risk women, antenatal surveillance should include daily home blood pressure
monitoring, where resources permit.

Low
⊕⊕OO

Conditional

If possible, high-risk women should be assessed by the formal health system at least once
every 2 weeks until 27+6 weeks and weekly thereafter; such assessments should include
symptom screening, blood pressure measurement, dipstick proteinuria assessment
(if women are hypertensive) and, where available, hemoglobin, platelet count, serum
creatinine, and serum aspartate transaminase (AST) or alanine aminotransferase (ALT)
tests.

Low
⊕⊕OO

Conditional

In high-risk women, fetal surveillance should include fetal biometry, amniotic fluid
assessment, and umbilical artery Doppler, at least every 2–4 weekly where resources
permit. Should evidence of decreased fetal growth velocity become evident, both
maternal and fetal surveillance should be increased to at least weekly assessments,
even if the woman remains normotensive and asymptomatic.

Low
⊕⊕OO

Conditional

Where there is either limited or no access to ultrasound, serial symphysis–fundal height
measurements should be performed at least every 2 weeks during the care of high-risk
women by appropriately trained care providers (preferably the same each time).

Low
⊕⊕OO

Strong

a

“High risk” for the first trimester is defined according to Poon et al.1 Otherwise, high risk is defined by the ISSHP criteria.6

The Edinburgh antenatal care visit paradigm was developed in

compared with the Edinburgh paradigm36; hence the introduction of

large part to assist in screening for and diagnosing pregnancy hyper-

the eight-encounter model in 2017.37 Both blood pressure measure-

tension. The introduction of that paradigm of 4-weekly visits from

ment and proteinuria screening are integral elements of a WHO-

booking until 27+6 weeks, fortnightly visits from 28+0–35+6 weeks,

compliant antenatal visit program; however, the inclusion of regular

and weekly visits from 36+0 weeks until delivery was associated with

proteinuria assessment at all visits did not follow formal evidence

accelerated improvements in maternal survival. The World Health

review. Canada has undertaken such a review, and the national ad-

Organization (WHO) focused antenatal care model (four visits per

vice now specifically states that proteinuria screening should not be

pregnancy) was associated with less optimal perinatal outcomes

performed as part of routine antenatal care.38
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B LO O D PR E S S U R E , D E LI V E RY, A N D P OS TPA RT U M M A N AG E M E NT

7.1 | Place of care

Pragmatic practice advice

Quality of evidence

We recommend that women with pre-eclampsia should be assessed in hospital when first
diagnosed. Thereafter, some women may be managed as outpatients once it is established that
their condition is stable, and they can be relied upon to monitor blood pressure at home and
seek medical advice when there is rising/raised blood pressure.

Low
⊕⊕OO

Strength of
recommendation
Strong

The level of blood pressure itself is not a reliable way to strat-

develop serious organ dysfunction at relatively mild levels of

ify immediate risk in pre-e clampsia because some women may

hypertension.

7.2 | Antenatal maternal and fetal surveillance

Best practice advice

Quality of evidence

Strength of
recommendation

Maternal surveillance
We recommend that beyond blood pressure and proteinuria measurement, maternal assessment of
women with gestational hypertension, with or without proteinuria, should include components
of PIERS models (Pre-eclampsia Integrated Estimate of Risk Scores).

Moderate
⊕⊕⊕O

Conditional

We recommend that maternal laboratory testing should occur, at minimum, twice weekly for
inpatients.

Low
⊕⊕OO

Conditional

Low
⊕⊕OO

Conditional

Low
⊕⊕OO

Conditional

We suggest that maternal laboratory testing should occur weekly for outpatients.
Fetal surveillance
We recommend that where available, ultrasound be performed once every 2 weeks to assess fetal
growth, and at least once every 2 weeks to assess liquor volume and umbilical artery Doppler.
We recommend fetal cardiotocography (CTG) to monitor the fetal condition. In early fetal growth
restriction before 34 weeks, CTG should be performed daily.
Preferably by using computerized CTG to assess fetal heart rate variation.
We recommend at <34 weeks when there is fetal growth restriction, and where trained personnel
are available to perform and interpret the assessment, Doppler velocimetry of the ductus
venosus be performed, to assess the risk of adverse perinatal outcome.
We recommend against the use of the biophysical profile to monitor growth restricted fetuses at
risk in hypertensive pregnancy.
We suggest that at ≥32 weeks, if there is no access (or access is not yet possible) to fetal CTG and
ultrasound, the following should be used to assess fetal risk in hypertensive pregnancy: maternal
age, symptoms, and dipstick proteinuria.

Low
⊕⊕OO
Low
⊕⊕OO

Strong

Low
⊕⊕OO

Conditional

Low
⊕⊕OO

Conditional

Low
⊕⊕OO

Conditional

Conditional

Beyond assessment of blood pressure and proteinuria, maternal

With ready access to laboratory results, fullPIERS includes gestational

assessment should include the components of the fullPIERS models

age, chest pain/dyspnea, pulse oximetry, platelet count, serum creat-

(https://pre-empt.obgyn.ubc.ca/evidence/fullpiers) that are predic-

inine, and aspartate transaminase (AST) or alanine aminotransferase

tive of adverse maternal outcome in hypertensive pregnancy and pre-

(ALT).40 While clonus reflects central nervous system irritability, the

eclampsia, specifically, when performed at least twice weekly.39–41

reproducibility of clonus testing (in the maternity setting) and its inde-

The models incorporate gestational age but are not restricted to a spe-

pendent predictive value for adverse outcome is uncertain.

cific gestational age range, like the PREP model developed for use in

The fetuses of women with hypertension are at increased risk

pre-eclampsia before 34 weeks.42 Without ready access to laboratory

of mortality and morbidity. While multiple methods are available

results, the miniPIERS model includes systolic blood pressure, dipstick

to monitor the fetuses of hypertensive pregnancies, no strategy

proteinuria, parity, gestational age, and symptoms (headache/visual

of various methods and timings has been recognized to be supe-

symptoms, chest pain/dyspnea, abdominal pain with vaginal bleeding);

rior in this group or in general. As the fetus with growth restric-

model performance is improved with the addition of pulse oximetry.39

tion and/or reduced liquor volume is at particular risk of stillbirth
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and neonatal mortality and morbidity, ultrasonographic assess-

In hypertensive pregnancy with early fetal growth restriction, we

43,44

recommend against using the biophysical profile for fetal surveil-

Trials suggest that in high-risk pregnancies, Doppler ultrasound

lance as it may be falsely reassuring and, when abnormal, is a late

of the umbilical artery may reduce perinatal death and obstetric

finding.43,55–57 Where available, cardiotocography should be per-

ment of fetal growth and liquor volume is recommended.

45

intervention, but the evidence is not definitive ; it is important

formed daily based on the 5% daily risk of abnormality seen in the

to note that near or at term, a normal umbilical artery Doppler

TRUFFLE study. 58

does not exclude fetal compromise.

46–4 8

The cerebroplacental

Without ready access to methods of fetal surveillance beyond fetal

ratio is better in the prediction of adverse outcome in small-for-

heart rate monitoring, maternal characteristics may identify perinatal

gestational age fetuses at term.49

risk. Maternal age, number of symptoms (0, 1, or ≥2), and dipstick pro-

At <34 weeks in the presence of fetal growth restriction, the

teinuria can be used to estimate perinatal risk at ≥32 weeks; before this

addition of Doppler ultrasound of the ductus venosus may be ben-

time, risk is almost entirely driven by gestational age.59 Women at in-

eficial, as absent or reserved end-diastolic velocities are associated

creased risk may benefit from transfer to facility-based care, but this

with a substantially increased risk of stillbirth50 ; initiation of deliv-

model requires external validation to confirm performance. With access

ery for abnormal ductus venosus Doppler, short-term fetal heart

to laboratory testing, elevated serum uric acid (particularly when gesta-

rate variation by computerized cardiotocography (cCTG), and/

tional age-corrected) may further identify fetuses at risk.60 With access

or spontaneous fetal heart rate decelerations is associated with

to angiogenic markers, a low PLGF (<50 pg/mL) may identify fetuses at

improved neurodevelopmental outcomes among survivors. 51–5 4

particular risk of stillbirth in low-and middle-income countries.61

7.3 | Nonpharmacological therapy

Pragmatic practice advice

Quality of evidence

There is insufficient evidence to recommend for or against restricted activity, in hospital or at
home, for any hypertensive disorder of pregnancy.

Low
⊕⊕OO

Of note, for women with gestational hypertension, some bed
rest in hospital was superior to unrestricted activity at home, but
the trial was small (218 women) and performed 25 years ago.

62

Strength of
recommendation
Conditional

a similar trial that examined different endpoints, women preferred
unrestricted activity at home.63,64

In

7.4 | Antihypertensive therapy

Best practice advice

Quality of evidence

Strength of
recommendation

Nonsevere hypertension
We recommend that elevated blood pressure in pregnancy be treated with antihypertensive
therapy and that the target systolic blood pressure and diastolic blood pressure should be 135
and 85 mmHg, respectively.

High
⊕⊕⊕⊕

Strong

We recommend that oral labetalol, nifedipine, and methyldopa be considered as first-line
antihypertensive agents for nonsevere hypertension.

Moderate
⊕⊕⊕O

Strong

Moderate
⊕⊕⊕O

Strong

Moderate
⊕⊕⊕O

Strong

Severe hypertension
We recommend that severe hypertension in pregnancy be treated urgently with antihypertensive
therapy, in a monitored setting.
We recommend that severely elevated diastolic blood pressure be lowered to a target of
85 mmHg, but gradually over hours to days.
We recommend that oral nifedipine, oral labetalol, intravenous labetalol, and intravenous
hydralazine be considered as first-line antihypertensive agents for severe hypertension.

Low
⊕⊕OO

Strong

The threshold for treatment of hypertension in pregnancy is a

platelets and elevated liver enzymes with symptoms based on the find-

systolic blood pressure ≥140 mmHg and/or a diastolic blood pressure

ings from randomized controlled trials, including the CHIPS trial.65,66

≥90 mmHg. This is true whether the hypertension is chronic, gestational,

While CHIPS enrolled women with chronic or gestational hypertension,

or due to pre-eclampsia. Treatment reduces the likelihood of develop-

almost half of the women developed pre-eclampsia and all stayed on

ing severe maternal hypertension and other complications, such as low

their allocated blood pressure control for an average of 2 weeks before
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birth. In the CHIPS trial, severe hypertension was similar to pre-eclampsia
67

in being a surrogate marker for adverse outcomes.

placebo/no therapy for severe hypertension, such trials would be unethical, and there is international consensus that these women require

The target blood pressure for antihypertensive treatment should

urgent treatment to decrease the risk of intracerebral events and

be a diastolic blood pressure of 85 mmHg, as in CHIPS; this approach

other complications; severe hypertension is a surrogate marker for

achieved a mean blood pressure of 133/85 mmHg by use of a simple

adverse maternal and perinatal outcomes and these women require

algorithm in which antihypertensive drugs were reduced or ceased if

close monitoring even after blood pressure has come down.67 Advice

diastolic blood pressure fell below 80 mmHg and increased or started

to lower blood pressure gradually is based on exacerbation of cerebral

if it rose above 85 mmHg, or systolic blood pressure was ≥160 mmHg

ischemia in stroke and an excess of adverse perinatal outcomes among

(regardless of diastolic blood pressure) (Figure 1).

women treated with agents that lower blood pressure quickly.70–72

The approach to hypertension is the same for all women, including

There is no antihypertensive agent that has proven to be superior

those with comorbidities such as chronic renal disease.68 The only

to others for treatment of severe hypertension in pregnancy. A recent

exception is white-coat hypertension unless women develop blood

study showed that oral nifedipine retard use resulted in a greater fre-

pressure levels ≥160/110 mmHg in the office/hospital setting.

quency of primary outcome attainment (blood pressure control, de-

No antihypertensive agent has been shown to be superior to

fined as 120–150 mmHg systolic and 70–100 mmHg diastolic) within

others for treatment of nonsevere hypertension, but oral labetalol,

6 hours with no adverse outcomes) than oral labetalol or methyldopa

nifedipine, and methyldopa are used most commonly. Less com-

use.71 However, oral nifedipine, oral labetalol, intravenous labetalol,

monly used but acceptable antihypertensive agents include other

and intravenous hydralazine are most commonly used. Traditionally,

69

Other potential agents are less

oral nifedipine (often capsules) or parenteral antihypertensive agents

desirable but not contraindicated, based on unproven concerns

have been used to treat severe hypertension, but other oral agents,

about maternal tachycardia when used alone (i.e. hydralazine), still-

such as oral labetalol (200 mg orally hourly, for three doses if neces-

birth in the setting of pre-eclampsia (i.e. prazosin), or theoretical haz-

sary) or oral methyldopa (1 g as a single dose) may be effective in the

ards of reduced maternal circulating volume (i.e. diuretics).

majority of women.69,71,73 They are worth considering as an alterna-

beta-blockers (e.g. oxprenolol).

While all hypertension in pregnancy warrants antihypertensive

tive, particularly during transfer to a monitored setting.

therapy, treatment is warranted urgently when the blood pressure

While oral antihypertensives can be given during labor, these are

elevation is severe: to levels of systolic blood pressure ≥160 mmHg

associated with reduced gastrointestinal motility and drug absorp-

or diastolic blood pressure ≥110 mmHg. While there are no trials

tion. As such, if blood pressure control is suboptimal during labor,

that have demonstrated that antihypertensive therapy is superior to

parenteral agents may be needed.

F I G U R E 1 Algorithm for “tight” blood pressure control used in the CHIPS trial.a *If systolic blood pressure is ≥160 mmHg, increase
dose of existing medication or start new antihypertensive medication to get systolic blood pressure <160 mmHg, regardless of diastolic blood
pressure (dBP). aAdapted figure reprinted with permission from Wiley: Magee LA, Khalil A, von Dadelszen P. Pregnancy hypertension diagnosis
and care in COVID-19 era and beyond. Ultrasound Obstet Gynecol. 2020;56:7–10. © 2020 ISUOG. Permission for original figure reprinted from
Pregnancy Hypertens. 2019;18. Magee LA, Rey E, Asztalos E, et al. Management of non-severe pregnancy hypertension –a summary of the
CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications. 156–162. © 2019, with permission from Elsevier.
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7.5 | Magnesium sulfate and other strategies for women with pre-eclampsia

Best practice advice

Quality of evidence

We recommend magnesium sulfate to prevent recurrent seizures for women with eclampsia.

High
⊕⊕⊕⊕

We recommend magnesium sulfate as a neuroprotective agent preventing perinatal morbidity in
preterm pre-eclampsia requiring delivery at <32 weeks.

Strength of
recommendation
Strong
Strong

We recommend magnesium sulfate to prevent eclampsia for women with pre-eclampsia who either
have blood pressure ≥170/110 mmHg and ≥3+ proteinuria, or blood pressure ≥150/100 mmHg,
≥2+ proteinuria, and neurological signs or symptoms of “imminent eclampsia.”

Moderate
⊕⊕⊕O

High
⊕⊕⊕⊕

Strong

For prevention of recurrent or first seizures, magnesium sulfate should be used in standard dosage,
usually a 4-g intravenous loading dose followed by maintenance of either 5 g intramuscularly to
each buttock every 4 hours or 1 g per hour intravenously, for 24 hours.

Moderate
⊕⊕⊕O

Strong

We do not recommend plasma volume expansion for women with pre-eclampsia.

Moderate
⊕⊕⊕O

Strong

There is clear evidence that magnesium sulfate halves both the

This includes continuation of magnesium sulfate for 24 hours, until

incidence of seizures among women with pre-eclampsia, and the

further evidence is published on the effectiveness of alternative dos-

recurrence of seizures among women with eclampsia.74 Among

ing that is either smaller in dose or abbreviated in duration. Monitoring

women with pre-eclampsia, the number needed to treat (NNT) is

of serum magnesium levels is not necessary unless there is reduced

approximately 100 to prevent one seizure. However, it is contro-

kidney function or another reason for heightened risk of toxicity.

versial whether all women with pre-eclampsia should receive mag-

There is evidence that antenatal magnesium sulfate given prior to

nesium sulfate due to an elevated risk of cesarean delivery, more

preterm birth for fetal neuroprotection prevents cerebral palsy and

maternal adverse effects, and higher costs (i.e. USD [year 2001]

reduces the combined risk of fetal/infant death or cerebral palsy. Benefit

$23 000 to prevent one seizure if administered to all women with

is seen regardless of the reason for preterm birth, with similar effects

75

pre-eclampsia).

As the NNT is lower among women with “severe”

across a range of preterm gestational ages and different regimens.76

pre-eclampsia (approximately 50), it is reasonable in well-resourced

Hypertensive pregnancy is a major cause of iatrogenic prema-

settings to restrict magnesium sulfate use to “severe” pre-eclampsia

turity. Antenatal corticosteroids for acceleration of fetal pulmonary

as defined in the Magpie trial74: blood pressure ≥170/110 mmHg and

maturity should be used in hypertensive as in other pregnancy based

≥3+ proteinuria, or blood pressure ≥150/100 mmHg with ≥2+ pro-

on gestational age criteria and local policy.

teinuria and neurological signs or symptoms of “imminent eclampsia”

Plasma volume expansion with colloid solutions does not

(which was not defined but is taken to mean headache, visual symp-

improve pregnancy outcomes, and may increase the need for ce-

toms, or clonus). Each unit should have a consistent policy concern-

sarean delivery, decrease pregnancy prolongation, and increase

ing their use of magnesium sulfate.

the risk of pulmonary edema.77,78 For women with pre-e clampsia,
74

The dosing regimens used in the Magpie trial should be used (e.g.
4 g intravenous loading and 1 g per hour maintenance intravenously).

total fluid intake in labor should be restricted to approximately
80 mL per hour.79

7.6 | Timed delivery

Best practice advice

Quality of evidence

We recommend delivery for women with any hypertensive disorder of pregnancy at any
gestational age in the presence of one or more of the conditions listed below:
• abnormal neurological features such as severe intractable headache, repeated visual
scotomata, eclampsia, or stroke;
• repeated episodes of severe hypertension despite maintenance treatment with three
classes of antihypertensive agents;
• pulmonary edema or oxygen saturation <90%;
• progressive thrombocytopenia (particularly <50 × 109/L or need for transfusion);
• abnormal and rising serum creatinine;
• abruption with evidence of maternal or fetal compromise;
• nonreassuring fetal status (including intrauterine fetal death).

Moderate
⊕⊕⊕O

Strength of
recommendation
Strong
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Best practice advice

Quality of evidence

Strength of
recommendation

<34+0 weeks (very preterm):
We suggest that at <34+0 weeks, expectant care be undertaken for women with chronic or
gestational hypertension unless there is an indication for birth.
We suggest expectant management be considered for women with pre-eclampsia at
<34+0 weeks, but only in tertiary centers with experience of careful noninvasive
monitoring of the mother and capable of support for very preterm infants.

Very low
⊕OOO

Conditional

Moderate
⊕⊕⊕O

Conditional

Very low
⊕OOO

Conditional

34+0–36+6 weeks (late preterm):
We suggest that at 34+0–36+6 weeks, expectant care be undertaken for women with
chronic or gestational hypertension unless there is an indication for birth.
We suggest that initiation of delivery be discussed for women with pre-eclampsia at 34+0–
35+6 weeks, as it decreases maternal but increases neonatal risk.
We recommend initiation of birth for women with pre-eclampsia at 36+0–36+6 weeks.
37+0–41+6 weeks (term):
We suggest that for women with chronic or gestational hypertension, initiation of delivery
be discussed at 38+0 to 39+6 weeks but should be advised from 40+0 weeks.
We suggest that for women whose gestational hypertension developed preterm, initiation
of delivery can be offered at 38+0 to 39+6 weeks, but should be advised by 40+0 weeks.
We recommend delivery be initiated within 24 hours for women with gestational
hypertension or pre-eclampsia that develops at term.

Moderate
⊕⊕⊕O

Conditional

Moderate
⊕⊕⊕O

Strong

Low
⊕⊕OO

Conditional

Moderate
⊕⊕⊕O
Moderate
⊕⊕⊕O

Strong
Strong

Indications for planned birth, regardless of gestational age

neonatal respiratory morbidity in the Dutch HYPITAT-II trial (703

or hypertensive disorder, include those end-
o rgan complica-

women) in which 1% of women received antenatal steroids. 82 On

tions associated with a heightened risk of maternal or perinatal

the other hand, in the PHOENIX trial (900 women), initiation of

death.

80

For women with pre-e clampsia, neither the serum uric

birth was associated with reduced maternal morbidity and more

acid nor the level of proteinuria should be used as indications

neonatal care unit admission, but no increase in neonatal respira-

for delivery.

tory morbidity. 83 Although the women in the PHOENIX trial were at

At <34

+0

weeks there are no data to indicate that women with

higher risk of adverse outcomes (based on all having pre-eclampsia

chronic or gestational hypertension would benefit from delivery

versus just under half in the HYPITAT-II trial), a key consideration

unless there is a specific indication for birth, as listed above. At this

was that 60% of women in the PHOENIX trial received antenatal

gestational age for women with pre-eclampsia, small randomized

corticosteroids, which may explain why no difference was seen in

controlled trials suggest that expectant care may improve neonatal

respiratory distress in this trial. 83 Reassuringly, however, initiation

outcomes without increasing maternal risk.81 However, expectant

of birth (versus expectant care) has been associated with similar

care should be undertaken only where there are adequate services

child development and behavior outcomes at the age of 5 years. 84

to support the needs of a sick mother and baby.

An individual patient data meta-analysis suggested that neonatal

At 34+0–36+6 weeks there are few data to guide care of women

risk associated with initiation of birth at 34+0–36+6 weeks may be

with chronic or gestational hypertension. One study on timing of

focused on the 34+0–35+6 window, with no increased risk from

birth included women with chronic hypertension, but they had

36+0 weeks85; this finding is consistent with subgroup analyses in

either superimposed pre-
eclampsia or “deteriorating hyperten-

the PHOENIX trial. 83

sion” that satisfies the definition of superimposed pre-eclampsia by

At term gestational age, women with chronic hypertension may

The HYPITAT-II trial included 182 women with

benefit from birth at 38+0–39+6 weeks, in terms of reduced inci-

gestational hypertension. While outcomes were similar to those of

dence of severe hypertension, stillbirth, and cesarean delivery, but

women with pre-eclampsia in subgroup analyses, initiation of birth

the evidence is primarily observational in nature86,87; randomized

may have been associated with reduction in maternal but an increase

controlled trial data on 50 women suggest that initiation of delivery

in neonatal risk; however, the number of women randomized was

at 37+0 weeks is associated with an excess of neonatal morbidity.88

many guidelines.

82

insufficient on which to base a recommendation.

82

There is one ongoing trial of timed delivery at term that is including

At 34+0–36+6 weeks for women with pre-eclampsia, random-

women with chronic hypertension and preterm gestational hyper-

ized controlled trial data suggest that initiation of birth, which

tension (ISRCTN77258279). Women with gestational hypertension

results in delivery an average of 5 days earlier than ongoing ex-

or pre-eclampsia that develops at term should be offered initiation of

pectant care, is associated with reduced maternal morbidity and

birth within 24 hours based on the results of the HYPITAT-I trial.89 A

severe hypertension, but increased neonatal morbidity, particularly

meta-analysis of the PHOENIX trial, relevant women in HYPITAT-II,

respiratory problems. Initiation of birth was associated with more

and other relevant trials is underway.
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It is important to note that labor induction does not increase ce-

vaginal deliveries in the group routinely delivered.83 Furthermore,

sarean delivery. In fact, in pregnancy hypertension trials, labor in-

initiation of birth versus expectant care trials have been conducted

duction at or near term has been associated with a nonsignificant

in environments in which hypertension is treated when substantially

reduction in cesarean delivery. In labor induction trials taken together,

elevated, such as ≥150/100 83 or ≥160/110 mmHg,84,91 an important

90

labor induction decreased (not increased) cesarean delivery.

The

PHOENIX trial was associated with significantly more spontaneous

fact given the key outcome of severe hypertension, which can be
halved in incidence by antihypertensive therapy.65

7.7 | Postpartum care
Strength of
recommendation

Pragmatic practice advice

Quality of evidence

Blood pressure should continue to be monitored after delivery until 6 days postpartum, as it is
likely to be highest 3–6 days after birth.

Low
⊕⊕OO

Conditional

Low
⊕⊕OO

Conditional

We suggest that antihypertensive therapy that has been administered before birth be continued
after birth for as long as required to maintain blood pressure control.
We suggest that consideration be given to administering antihypertensive therapy for any
hypertension diagnosed before 6 days postpartum.
We suggest that nonsteroidal anti-inflammatory drugs for postpartum analgesia can be used
in women with pre-eclampsia unless blood pressure is uncontrolled, there is known renal
disease, or pre-eclampsia has been associated with placental abruption, acute kidney injury,
or other known risk factors for acute kidney injury (e.g. sepsis, postpartum hemorrhage).

Low
⊕⊕OO

Low
⊕⊕OO

Conditional

Conditional

Women may develop pre-
eclampsia or complications related

more advanced pre-eclampsia) suggest that NSAIDs do not increase

to pre-eclampsia (including eclampsia) for the first time after birth.

postpartum blood pressure, antihypertensive dose or need for dose

The highest blood pressure values may occur after women leave the

escalation, maternal complications, readmission, or opioid use.93–95

monitored inpatient setting, so it is important to have a blood pres-

Two randomized controlled trials of ibuprofen versus acetaminophen/

sure monitoring plan in place. Most antihypertensive agents, includ-

paracetamol for postpartum analgesia for “severe” pre-eclampsia have

ing ACE inhibitors are acceptable in breastfeeding, and up-to-date

been reassuring, finding either no increase in hypertension to 6 weeks

information can be obtained from the LactMed database (https://

after birth96 or an increase in blood pressure but no increase in the

toxnet.nlm.nih.gov/newtoxnet/lactmed.htm).

incidence of severe hypertension.97 As such, NSAIDs may be used for

Initial concerns that use of nonsteroidal anti-inflammatory drugs

postpartum analgesia following hypertensive pregnancy, as long as

(NSAIDs) may increase hypertensive urgency when used after birth

blood pressure control is not a problem and there are not other risk

following hypertensive pregnancy92 have not been confirmed.

factors for postpartum acute kidney injury (e.g. postpartum hemor-

Retrospective cohort studies (involving 538 women, mostly with

rhage or chronic kidney disease).
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LO N G -T E R M CO N S I D E R ATI O N S A S S O C I ATE D W ITH PR E- E C L A M P S I A

Pragmatic practice advice

Quality of evidence

We recommend that hypertensive pregnancy disorders should be acknowledged as predictors
of long-term maternal cardiovascular morbidity.

Moderate
⊕⊕⊕O

We recommend that the following measures are implemented at 6–12 weeks after birth,
and periodically thereafter, preferably yearly, following a pregnancy complicated by
hypertensive disorders:

Moderate
⊕⊕⊕O

Strength of
recommendation
Conditional
Conditional

• history and physical examination;
• blood pressure measurements;
• consider screening for other cardiovascular risk factors and for diabetes according to
additional risk factors.

Pre-
eclampsia is a well-
established risk factor for long-
term

independently associated with an increased risk of future heart

maternal and neonatal complications. Even after resolution of

failure (RR 4.19; 95% CI, 2.09–8 .38), coronary heart disease (RR

symptoms, an elevated risk for future maternal cardiovascular,

2.50; 95% CI, 1.43–
4.37), cardiovascular disease-
related death

cerebrovascular, and vascular disease exists.98–110 In addition, even

(RR 2.21; 95% CI, 1.83–2 .66), and stroke (RR 1.81; 95% CI, 1.29–

though less investigated, several studies have already demon-

2.55), highlighting once again the importance of lifelong moni-

strated that children antenatally exposed to pre-eclampsia are at an

toring of cardiovascular risk factors in women with a history of

increased risk of long-term cardiovascular, respiratory neuropsychi-

pre-e clampsia.

atric, gastrointestinal, and endocrinological morbidity.111–115

The strength of these data has already led the American Heart
Association (AHA) in 2011 to consider a history of pre-eclampsia
or gestational hypertension a major risk factor for development of

8.1 | Cardiovascular disease

cardiovascular disease.102 The American College of Obstetricians
and Gynecologists (ACOG), with the AHA, has published a presi-

Future maternal cardiovascular disease is probably the most stud-

dential advisory with the AHA providing specific recommendations

ied long-term consequence of hypertensive disease of pregnancy.

for cardiovascular disease risk factors screening for women with

Multiple systematic reviews of controlled studies evaluated the

prior pre-eclampsia that was preterm (<37 weeks) or recurrent.103

risk of late cardiovascular events in women with and without a his-

In this group of women, ACOG recommends yearly screening of

98

tory of hypertensive disease of pregnancy. In 2007, Bellamy et al.

blood pressure, lipids, fasting blood sugar, and body mass index.

published their results of a systematic review and meta-analysis

This recommendation relates only to women with preterm or recur-

on the risk for future cardiovascular morbidity of women who ex-

rent pre-eclampsia as they are at the highest risk of cardiovascular

perienced pre-e clampsia. They analyzed 25 studies including more

mortality; screening for women with prior term pre-eclampsia was

than 3 million women, of whom about 5% had a history of pre-

not addressed.

eclampsia, and reported the relative risk (RR) for hypertension to

The observation made by ACOG between term and preterm pre-

be 3.70 (95% CI, 2.70–5.05), for ischemic heart disease 2.16 (95%

eclampsia is important as the magnitude of the above findings is fur-

CI, 1.86–2 .52), for stroke 1.81 (95% CI, 1.45–2 .27), and for venous

ther emphasized by the severity, recurrence, and gestational age of

thromboembolism 1.79 (95% CI, 1.37–2 .33). In their analysis, there

onset of the hypertensive disorder.

was also a relative risk of 1.49 (95% CI, 1.05–2 .14) for overall mortality after pre-
e clampsia. Another meta-
analysis that included
case–
control and cohort studies found that the odds ratio for

8.2 | Early and late onset of pre-eclampsia

cardiac disease was 2.47 (95% CI, 1.22–5.01) in the case–control
studies, and the relative risk in the cohort studies was 2.33 (95%

Women with early-onset pre-eclampsia are at a significant higher

CI, 1.95–2 .78). They also reported an increased risk of cerebrovas-

risk for vascular disease compared to late-onset pre-eclampsia. A

cular disease (RR 2.03; 95% CI, 1.54–2 .67) and cardiovascular mor-

Norwegian population-based cohort study of 626 272 deliveries

tality (RR 2.29; 95% CI, 1.73–3 .04). Likewise, a review of 43 studies

found that women who had pre-eclampsia had a 1.2-fold higher

found pre-e clampsia to be associated with an approximate two-

long-term risk of death (95% CI, 1.02–1.37) than women who did

fold increase in odds of cardiovascular disease and cerebrovascu-

not have pre-eclampsia. When stratified by term or preterm birth,

lar disease, and a three-fold increased risk of hypertension.101 In

given that pre-eclampsia might be more severe if onset is preterm,

100

analyzed 22 studies with more than 6.4 million

the risk increased to 2.71 (95% CI, 1.99–3.68) in women with pre-

women including more than 258 000 women with pre-e clampsia.

2017, Wu et al.

eclampsia and preterm delivery compared to women without pre-

Adjusting for potential confounders, such as age, body mass index,

eclampsia who delivered at term. Furthermore, the risk of death

and diabetes mellitus, they demonstrated that pre-e clampsia was

from cardiovascular causes among women with pre-eclampsia and

|
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preterm delivery was 8.12-fold higher (95% CI, 4.31–15.33) than

first pregnancy was pre-e clamptic, both compared with multipa-

women without pre-
eclampsia who delivered at term, whereas

rous women without hypertensive disease. To note, the corre-

women with pre-eclampsia who delivered at term had only a 1.6-

sponding relative risks for stroke in the women in this study were

fold (95% CI, 1.01–2.7) higher risk of cardiovascular death.104 Similar

1.5 and 1.2.

results were reported by other studies,105 where the hazard ratio for
cardiovascular death associated with preterm pre-eclampsia (delivery <37 weeks) was 3.7 times higher but only 1.6 times higher among

8.5 | End-stage renal disease

women with prior term pre-eclampsia, both compared to normotensive pregnancies.105

Women with pre-eclampsia may also be at increased risk of developing end-stage renal disease (ESRD) later in life, but the absolute risk
is small. A retrospective study from Norway found that women with

8.3 | Severity of pre-eclampsia

pre-eclampsia in their first pregnancy had a four-fold increase in risk
of ESRD compared with women without pre-eclampsia (RR 4.7; 95%

A dose–response relationship has been observed between the

CI, 3.6–6.1), but the absolute risk of ESRD was less than 1% within

severity of pre-e clampsia and the long-term risk of cardiovascu-

20 years.109 Similarly, in another study,106 women with pre-eclampsia

106

lar disease. In 2015, Kessous et al.

reported a significant asso-

had an increased risk for renal disease later in life that was also associ-

ciation between pre-e clampsia and cardiovascular morbidity and

ated with the severity of pre-eclampsia (no pre-eclampsia, mild pre-

showed a linear association between the severity of pre-e clampsia

eclampsia, severe pre-eclampsia, and eclampsia) although the total

(no pre-e clampsia, mild pre-e clampsia, severe pre-e clampsia, and

prevalence was small (0.1% vs 0.2% vs 0.5% vs 1.1%, respectively;

eclampsia) and the risk of future cardiovascular morbidity (2.75%

P = 0.001). ESRD may possibly be the sequel of a subclinical renal

vs 4.5% vs 5.2% vs 5.7%, respectively; P = 0.001). Similar results

disease during pregnancy, but it is also possible that pre-existing risk

107,108

and were also found in the

factors predisposed these women to both pre-eclampsia and ESRD,

meta-a nalysis by McDonald et al.99 whereby mild, moderate, and

just as these women are at increased risk for other cardiovascular

severe pre-e clampsia were associated with relative risks of 2.00,

morbidity.

were published in earlier studies

2.99, and 5.36, respectively, of developing future cardiovascular
disease.

8.6 | Ophthalmic disease

8.4 | Recurrence of pre-eclampsia

The microangiopathic lesions thought to be caused by pre-eclampsia
may also expose women to long-term ophthalmic complications such

A significant linear association was documented between the

as diabetic retinopathy and retinal detachment. While investigating

number of previous pregnancies with pre-e clampsia and the risk

over 100 000 deliveries, 8.1% of them complicated with pre-eclampsia,

for future cardiovascular disease.106 This association was also

a recent study found that a history of pre-eclampsia in pregnancy was

108

independently associated with higher rates of ophthalmic morbidity

reported in the registry-b ased cohort study from Denmark,

where multiparous women had a 2.8 (95% CI, 2.3–3 .4) increased

that was also associated with the severity (no pre-eclampsia, mild pre-

risk after two pregnancies complicated by pre-e clampsia com-

eclampsia, severe pre-eclampsia, and eclampsia) of the disease (0.2%

pared to a lower 1.3 (95% CI, 1.1–1 .5) increased risk if only their

vs 0.3% vs 0.5% vs 2.2%, respectively; P < 0.001).110
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C H O I C E O F AU TO M ATE D B LO O D PR E S S U R E M O N ITO R S

Best practice advice

Quality of evidence

We recommend that if automated blood pressure devices are used, only automated blood
pressure devices that have been shown to be accurate in pregnancy and pre-eclampsia
should be used.

Moderate
⊕⊕⊕O

Strength of
recommendation
Strong

Due to the physiological cardiovascular adaptation in
pregnancy, oscillometric blood pressure devices are usually
inaccurate in pre-e clampsia and tend to underestimate blood
pressure. Therefore, only devices that have been shown to be
accurate in measuring blood pressure in pregnancy should be
relied upon. Validation will ensure both calibration and the software/hardware correctly obtains an accurate measurement.

Box 2 Blood pressure devices validated for use in
pregnancy and pre-eclampsia117a
Hospital/clinic
devices

116

Dinamap ProCare 400
A&D UM-101
Nissei DS-4 00

A number of validation protocols have been published, includ-

Omron HEM907

ing by the British Hypertension Society, the European Society

Welch Allyn QuietTrak (Ambulatory)

of Hypertension, and the Association for the Advancement

BP Lab (Ambulatory)

of Medical Instrumentation. These protocols have recently

PAR Medizintechnik & Co. Physio-
Port (Ambulatory)

been incorporated into an International Organization for
Standardization standard. There are greater than 4000 devices
on the market and a small number are accurate in pregnancy.117
Devices that have been proven valid and accurate should be

Portable devices
(suitable for
home use)

used, given the consequences of inaccurate blood pressure

Omron M7 (HEM 780E)
Omron MIT
Omron MIT Elite
Omron HEM-9210T

measurement during pregnancy. Box 2 demonstrates devices

Omron BP760N (HEM-7320-Z )

that can be recommended.

Microlife WatchBP Home A
Microlife BP 3BTO-A
Microlife BP 3AS1-2

9.1 | Blood pressure devices suitable for low-
resource settings

Microlife WatchBP Home A BT
Microlife WatchBP Home S

Mercury sphygmomanometry is no longer available. While aneroid

Microlife CRADLE VSA

devices are used commonly, they may over-or underestimate blood

Andon iHealth Track

118

pressure,

and they need to be regularly calibrated. Liquid-crystal

sphygmomanometery119 is the best alternative. Alternatively, the
CRADLE VSA device (Microlife Corporation; Widnau, Switzerland)

a
The STRIDE BP website (https://www.stridebp.org/bp-
monitors) provides an updated list of validated blood pressure
monitors.

has been validated for use in pregnancy, as well as in normotensive,
hypertensive, and hypotensive women, meeting the WHO’s requirements for suitability for low-and middle-income countries.120 It is
reasonably costed (USD $20), robust, easy to use, and can be port-

that introduction of the device in conjunction with an educational

able. It does not require calibration. It can be used in both an aus-

package resulted in no significant benefit or harm (OR 1.22; 95%

cultatory or oscillometric function. It has low power requirements

CI, 0.73–2.06; P = 0.45) as the intercluster variation was too great

as it is charged from a micro-USB charger. An early warning score

to demonstrate any effect.122 However, a composite of maternal

traffic light is triggered by raised blood pressure or an abnormal

outcome (of death, eclampsia, and/or hysterectomy) was lower at

shock index (pulse:systolic blood pressure). Healthcare profession-

an individual level before intervention (79.4 per 100 000 deliveries)

als have given unanimously positive feedback for the traffic light

compared with after intervention (72.8 per 100 000 deliveries).122

121

early warning system, and pregnant women unanimously agree.

A

In some countries there were highly significant effects in the pri-

stepped-wedge, cluster-randomized trial of the CRADLE VSA device

mary outcome, and therefore further work regarding mechanism is

in 10 clusters in eight low-and middle-
income countries found

needed.122
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The introduction of the sFlt-1/PLGF ratio is also expected to reduce
the number of hospitalizations at first presentation, before developing pre-eclampsia, from 36% to 16%.128 The authors concluded that
the introduction of the sFlt-1/PLGF ratio into clinical practice results
in cost savings of £344 per patient compared with a non-test (cur-

The diagnosis of pre-eclampsia is based on blood pressure, maternal

rent clinical practice). Savings are primarily through an improvement

end-organ involvement (i.e. proteinuria, maternal symptoms, mater-

in diagnostic accuracy and reduction of unnecessary hospitalization.

nal signs, and laboratory test abnormalities), and fetoplacental dys-

Independent groups from Italy129 and Germany130 similarly

function. The criteria can result in false-positive diagnoses. This may

showed that the introduction of sFlt-1/PLGF into hospital practice

lead to unnecessary antenatal admissions, requests for multiple labo-

is cost saving. Savings are generated primarily through improvement

ratory tests and, not infrequently, the decision of iatrogenic preterm

in diagnostic accuracy and reduction in unnecessary hospitalization

delivery.

for women before the onset of pre-eclampsia.

A Health Technology Assessment was undertaken in the UK
123

in 2016

124–1 26

based on three published studies

In a middle-income country setting, a Brazilian group has com-

with the aim

pared the introduction of the ratio in a public and in a private hospital

to evaluate the diagnostic accuracy and cost-
effectiveness of

with expected different costs to manage patients with suspicion of

PLGF-b ased tests for patients referred to secondary care with

pre-eclampsia.131 Introduction of the sFlt-1/PLGF ratio test resulted

suspected pre-e clampsia at 20–37 weeks of pregnancy. The au-

in cost savings in both settings: public R$185.06 and private R$635.84

thors performed an independent economic analysis based on a de-

per patient compared to a scenario of non-test (current clinical prac-

cision tree model. The model evaluated costs127 from an NHS and

tice). As expected, savings were generated primarily through reduc-

Personal Social Services perspective. The total cost of managing a

tion in unnecessary hospitalization.131 Currently, there are no health

false-p ositive diagnosis of pre-e clampsia was £9576.25 and a true

economic data on supplementing current clinical practice with PLGF-

positive case of severe pre-e clampsia was £14,545.49. Based on

based tests in low-and lower middle-income countries.

the modelling study, the authors concluded that the model pre-

The implementation of angiogenic markers in clinical practice

dicts that when testing supplements routine clinical assessment

seems to improve clinical decisions regarding hospitalization, identi-

to rule out and rule in pre-e clampsia, the two tests are cost sav-

fying pregnant women with suspected pre-eclampsia who are at low

ing when performed between 20 and 35 weeks of gestation, and

risk of developing the disease and thus avoiding unnecessary pro-

marginally cost saving when performed at 35–37 weeks. Length of

cedures and thus cost saving. More complicated economic analysis

neonatal intensive care unit stay was the most influential parame-

looking at health system opportunity costs of unnecessary hospital-

ter in sensitivity analyses.

ization for suspected pre-eclampsia in overburdened public services

Another UK cost utility study showed that with the current clinical

at the cost of patients with other serious but less threatening con-

practice without the use of sFlt-1/PLGF ratio test information, 36%

ditions is not available, but will likely show improved cost benefit of

of women were hospitalized before a diagnosis of pre-eclampsia, of

supplementing current practice with PLGF-based testing. Predictive

whom only 27% subsequently developed pre-eclampsia. If the test

tools to improve clinical decision-making are not only important for

information was available, the proportion of women hospitalized could

individualizing management plans to improve outcomes, but also

be reduced to 16%, of whom 38% would have subsequently developed

have economic consequences for individuals, health systems, and

pre-eclampsia. Among women who were not hospitalized, approxi-

society, and the cost-effectiveness and cost utility of improved pre-

mately the same proportion subsequently developed pre-eclampsia.

dictive tools are required to ensure their optimal use.

26
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strategy have not been adequately studied in randomized trials.
Additionally, good adherence to treatment is paramount to successful prevention.137 Compliance is likely to be lower when aspi-

Considering the clear benefit of aspirin in reducing the risk of pre-

rin is given to the whole population than when recommended to a

term pre-eclampsia, its low cost, and safety profile, some investi-

selected high-risk group of women counselled based on individual

gators advocate for universal aspirin prophylaxis for pre-eclampsia

risk.138 Earlier trials in which pregnant women received aspirin on

prevention. It has been suggested that this would be a more cost-

the sole basis of being pregnant or nulliparous demonstrated an

effective strategy compared to using aspirin prophylaxis in women

increased frequency of bleeding episodes, low compliance with

determined to be at high risk through a process of screening, which

aspirin at only about 50%, and no reduction in the incidence of

132–135

has been considered rather complex for implementation.

pre-eclampsia.139,140 Analogously, universal aspirin for primary pre-

Nevertheless, possible benefits of a preventive strategy need to be

vention of cardiovascular events in healthy older adults resulted in

balanced with potential harm due to hemorrhagic and other adverse

a significantly higher risk of major hemorrhage but did not signifi-

events.136 Benefits of universal aspirin and long-term safety of this

cantly reduce the risk of cardiovascular disease.141
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There are three main objectives for further research. Firstly, more
prospective research is required to develop and evaluate risk stratification strategies in asymptomatic unselected women. Existing evidence on the use of multimarker algorithms is promising142–150 and
therefore such models require validation in other settings. Secondly,
evidence of the PLGF or sFlt-1/PLGF ratio published to date makes it
highly likely that the decision when to deliver women with gestational
hypertension or early disease of pre-eclampsia after 34+0 weeks of
gestation can be refined when these markers are added to clinical
decision-making. To date, the HYPITAT-I and II and PHOENIX randomized controlled trials are paramount on when to deliver women with
nonsevere, late-
onset hypertensive disease.82,83,91 The HYPITAT-
I
trial has shown that there is no benefit to either the mother or child in
prolonging pregnancy after 37 weeks of gestation in women with gestational hypertensive disease.89 The PHOENIX trial suggests delivery
will reduce maternal morbidity.83 There is a need for a meta-analysis
of the smaller studies, such as the HYPITAT-II trial, to ascertain the
effects on neonatal morbidity, mainly respiratory distress syndrome.
These findings must be re-evaluated after adding knowledge from
the PLGF or sFlt-1/PLGF ratio studies.
Thirdly, the role of the PLGF or sFlt-1/PLGF ratio to prevent fetal
and/or maternal adverse events in early-onset disease must be evaluated. The PARROT trial suggests maternal morbidity can be reduced
in women with suspected disease. 26 Although such a randomized
controlled trial is hard to pull through elsewhere, a PLGF or sFlt-1/
PLGF ratio cutoff for delivery in severe early-onset disease must be
evaluated. It has been shown previously in a case–control study that
the remaining pregnancy duration in women with pre-eclampsia and
an sFlt-1/PLGF ratio of greater than 655.2 is significantly reduced.
After 48 hours, only 29.4% (95% CI, 14.1–61.4%, P < 0.016) of the
women continued their pregnancy; only 5.9% (95% CI, 0.9–39.4%) of
the pre-eclampsia/HELLP patients with an sFlt-1/PLGF ratio above
655.2 continued their pregnancy for 7 days compared with 30.8%
(95% CI, 20.5–46.3%) below this level.151 Therefore, these values
and their ability to reduce maternal and/or fetal morbidity and mortality should be evaluated in a prospective, randomized design.
The studies presented here demonstrate that these different
risk stratification strategies may show clinical value in predicting
pre-eclampsia during the second and third trimester of pregnancy.
However, prospective randomized controlled trials are needed to
demonstrate improvement in maternal and neonatal outcomes, in
high-risk but also in low-risk populations.
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